SCHEMBL257543

SCHEMBL257543

Cc1cccc(-c2cc(=O)[nH]c3cc(C)nn23)c1

nearest known ligand 0.77

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.77
RAB9A P51151 3/20 0.77
CYP1A2 P05177 1/20 0.45
PARP1 P09874 1/20 0.45
XDH P47989 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.42
MAPT P10636 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B10 Q99714 1/20 0.40
PLAT P00750 1/20 0.39
TLR8 Q9NR97 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NOTUM Q6P988 1/20 0.38
GABRA1 P14867 1/20 0.38
GABRB2 P47870 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL257697 0.80 NPC1 (0.67) NPC1RAB9ACYP1A2PARP1KDM4E
SCHEMBL256938 0.79 NPC1 (0.74) NPC1RAB9ACYP1A2PARP1MAPT
SCHEMBL257549 0.79 NPC1 (0.74) NPC1RAB9ACYP1A2PARP1MAPT
SCHEMBL257310 0.77 NPC1 (0.68) NPC1RAB9ACYP1A2PARP1KDM4E
SCHEMBL15020774 0.75 NPC1 (0.60) NPC1RAB9ACYP1A2PARP1KDM4E
SCHEMBL10429722 0.73 L3MBTL1 (0.48) NPC1RAB9AXDHL3MBTL1MAPT
SCHEMBL257296 0.73 PLAT (0.53) NPC1RAB9AXDHL3MBTL1KDM4E
SCHEMBL461719 0.72 NPC1 (0.59) NPC1RAB9ACYP1A2PARP1L3MBTL1
SCHEMBL17731131 0.69 PLAT (0.71) NPC1RAB9APLAT
SCHEMBL5461696 0.69 NPC1 (0.56) NPC1RAB9ACYP1A2PARP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 NPC1 114/4885RAB9A 542/4885CYP1A2 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.